Unique technology, unique market

Xspray’s technology enables the creation of improved drugs, bettering or even saving patients’ lives. The unique technology also opens the opportunity to enter a multi billion market for cancer medicine, where competition is low.

Our vision

  • Latest report

    Xspray Pharma publishes Interim Report Q3, January – September 2019

  • Subscribe

    Get our latest press releases and reports

  • Upcoming calendar events

    14 May 2020 – Interim report, Jan-Mar, 2020

Press releases

All press releases

Xspray’s patented method to create amorphous forms of drugs, makes it possible to enter the market long before the generic companies, with a cheaper version of the original drug. The amorphous form of Xspray’s drug renders the original company’s secondary patent, which protects certain crystalline patterns, ineffective. This creates a window over several years, where Xspray becomes sole competitor on a multi billion dollar market.

We see a large potential for development the next few years. Out technology works for most of the 47 U.S. approved protein kinase inhibitors. The process of development and commercialisation we are establishing right now, on our first product HyNap-Dasa, will be applicable for all coming product candidates. We see a growing interest from our potential partners. This is an exciting time! Per Andersson, CEO

FAQ

Contact us

  • Please let us know if you have any questions about the company or the product. We will get back to you as soon as we can.
  • When clicked on Send I agree that my personal information will be saved. Read more
  • This field is for validation purposes and should be left unchanged.